100 related articles for article (PubMed ID: 1793228)
1. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells.
Waters CA; Snider CE; Itoh K; Poisson L; Strom TB; Murphy JR; Nichols JC
Ann N Y Acad Sci; 1991 Dec; 636():403-5. PubMed ID: 1793228
[No Abstract] [Full Text] [Related]
2. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
[TBL] [Abstract][Full Text] [Related]
3. PHA induces IL-2 receptors on B-CLL cells and is a potential biological response modifier for the LIL-2-diphtheria toxin, DAB486IL-2.
Bulger K; Padua F; Duff R; Pihan G; Nichols J; Murphy J; McCaffrey R
Leuk Res; 1994 Feb; 18(2):119-22. PubMed ID: 8107488
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood hairy cell leukemia cells express only low affinity IL-2 receptors.
Bulger K; Murphy J; Janckila A; Nichols J; McCaffrey R
Leuk Res; 1994 Feb; 18(2):101-4. PubMed ID: 8107487
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis.
Miller DD; Bach RG; Tio FO; Bailey SR; Waters CA; Woodworth TG; Nichols JC; Paige SB; Farrar M
Atherosclerosis; 1996 Sep; 126(1):1-14. PubMed ID: 8879429
[TBL] [Abstract][Full Text] [Related]
7. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.
Walz G; Zanker B; Murphy JR; Strom TB
Transplantation; 1990 Jan; 49(1):198-201. PubMed ID: 2301012
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice.
Pacheco-Silva A; Bastos MG; Muggia RA; Pankewycz O; Nichols J; Murphy JR; Strom TB; Rubin-Kelley VE
Eur J Immunol; 1992 Mar; 22(3):697-702. PubMed ID: 1547815
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2.
Zhang L; Waters C; Nichols J; Crumpacker C
J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.
Waters CA; Schimke PA; Snider CE; Itoh K; Smith KA; Nichols JC; Strom TB; Murphy JR
Eur J Immunol; 1990 Apr; 20(4):785-91. PubMed ID: 2140788
[TBL] [Abstract][Full Text] [Related]
12. The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells.
Zhang LJ; Waters CA; Poisson LR; Estis LF; Crumpacker CS
J Infect Dis; 1997 Apr; 175(4):790-4. PubMed ID: 9086131
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.
Bacha P; Williams DP; Waters C; Williams JM; Murphy JR; Strom TB
J Exp Med; 1988 Feb; 167(2):612-22. PubMed ID: 3126255
[TBL] [Abstract][Full Text] [Related]
14. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.
Kiyokawa T; Williams DP; Snider CE; Strom TB; Murphy JR
Protein Eng; 1991 Apr; 4(4):463-8. PubMed ID: 1881872
[TBL] [Abstract][Full Text] [Related]
15. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
[TBL] [Abstract][Full Text] [Related]
16. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
Cohen R; Jaffe ES; Stetler-Stevenson MA; Sausville EA; DeNigris EC; Woodworth T; Foss FM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):229-33. PubMed ID: 7834123
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
[TBL] [Abstract][Full Text] [Related]
18. Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.
Peraino JS; Schenk M; Li G; Zhang H; Farkash EA; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
J Immunol Methods; 2013 Dec; 398-399():33-43. PubMed ID: 24055128
[TBL] [Abstract][Full Text] [Related]
19. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis.
Bacha P; Forte SE; Perper SJ; Trentham DE; Nichols JC
Eur J Immunol; 1992 Jul; 22(7):1673-9. PubMed ID: 1623918
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.
Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K
Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
